Johnson & Johnson‘s (NYSE:JNJ) Janssen revealed data today from two Phase III trials of its investigational esketamine nasal spray in patients with treatment-resistant depression. The Titusville, N.J.-based company said that if approved by the FDA, esketamine would represent one of the first new approaches designed to treat refractory major depressive disorder in the last 50 years. Get […]
ACC ’18 Roundup: Abbott releases long-term HeartMate 3 data
Abbott (NYSE:ABT) touted two-year data yesterday from its trial designed to compare the company’s HeartMate 3 left ventricular assist device to its HeartMate 2 device in patients with advanced heart failure. Data from the study were published in The New England Journal of Medicine and presented at the American College of Cardiology’s 67th Annual Scientific Session. More […]
Xarelto, aspirin combo reduces risk of cardiovascular events in pivotal Ph3 trial
Johnson & Johnson (NYSE:JNJ) subsidiary Janssen touted data today from a pivotal Phase III trial showing that Xarelto plus aspirin reduced the risk of major cardiovascular events in patients with stable coronary and peripheral artery disease compared to aspirin alone. Treatment with Xarelto twice per day and aspirin once-daily cut the risk of major cardiovascular events […]
J&J touts first-in-human data for HIV vaccine
Johnson & Johnson (NYSE:JNJ) touted first-in-human clinical data today for its investigational HIV vaccine in development by its subsidiary, Janssen Pharmaceutical. The Phase I/IIa trial enrolled 393 healthy volunteers. According to the data, the vaccine was well-tolerated and triggered an HIV antibody response in 100% of participants. Get the full story at our sister site, Drug […]
7 medtech stories we missed this week: May 26, 2017
From Merck’s new licensing agreement to surgical study data being touted, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Merck inks exclusive licensing agreement for Alzheimer’s antibody Merck announced in a May 25 press release that it has entered an exclusive worldwide license agreement with Teijin Pharma. […]
Ichor Medical inks $85m drug-device deal with J&J
MassDevice Network
@MassDevice
LinkedIn
Google+